Endo Pharmaceuticals is still on the hunt for new deals, and according to its CEO David Holveck, the company is focusing on cancer and urology diagnostics and other health information technology. According to Bloomberg, the company has made six deals in the last five years.
"Everything in the treatment of patients starts with diagnostics," Holveck told Bloomberg at the J.P. Morgan Healthcare Conference in San Francisco. "A lot of the earlier diagnostics didn't have access to what we know today as molecular diagnostics that are much more specific."
The company's most recent deal came Sept. 28, when Endo purchased Qualitest Pharmaceuticals, a generic drug company, for $1.2 billion.
- read the Bloomberg report